Anti-IL-4R antibody and use thereof
AssigneesBeijing Wisdomab Biotechnology Co., Ltd, Genrix (Shanghai) Biopharmaceutical Co. Ltd., Chongqing Genrix Biopharmaceutical Co., Ltd.
InventorsZhigang Liu, Yulan Liu, Xiaobo Hao, Lei Jiang, Jingjing Guo
Life of this patent
Estimating the term…
Abstract
Disclosed in the present application are an antibody or an antigen-binding portion thereof binding to human IL-4R, a polynucleotide encoding the antibody or antigen-binding portion thereof, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or vector, a method for preparing and purifying the antibody, and the use of the antibody or antigen-binding portion thereof.
Claims18
An antibody that binds to human IL-4R comprising a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 and a light chain variable region comprising LCDR1, LCDR2 and LCDR, wherein
- the HCDR1 has the sequence of GFTFSSYAMS (SEQ ID NO:
- 33), the HCDR2 has the sequence of SITGGGGGIYYADSVKG (SEQ ID NO:
- 34), the HCDR3 has the sequence of DRISITIRPRYFGLDF (SEQ ID NO:
- 35), the LCDR1 has the sequence of RSSQSLLYSIGYNYLD (SEQ ID NO:
- 36), the LCDR2 has the sequence of LGSNRAS (SEQ ID NO:
- 37), and the LCDR3 has the sequence of MQSFKAPYT (SEQ ID NO:
- 38);
- or
- the HCDR1 has the sequence of GFTFSSYAMS (SEQ ID NO:
- 33), the HCDR2 has the sequence of SITGGGGGIYYADSVKG (SEQ ID NO:
- 34), the HCDR3 has the sequence of DRISITIRPRYFGLDF (SEQ ID NO:
- 35), the LCDR1 has the sequence of RSSRNVIYGNGYNYLD (SEQ ID NO:
- 39), the LCDR2 has the sequence of LGNNVAA (SEQ ID NO:
- 40), and the LCDR3 has the sequence of MQSLQAPYT (SEQ ID NO:
- 41);
- or
- the HCDR1 has the sequence of GFTFSSYAMS (SEQ ID NO:
- 33), the HCDR2 has the sequence of SITGGGGGIYYADSVKG (SEQ ID NO:
- 34), the HCDR3 has the sequence of DRISITIRPRYFGLDF (SEQ ID NO:
- 35), the LCDR1 has the sequence of RSSQNVYGNGYNYLD (SEQ ID NO:
- 42), the LCDR2 has the sequence of LGTNVAA (SEQ ID NO:
- 43), and the LCDR3 has the sequence of MQSLQAPYT (SEQ ID NO:
- 41);
- or
- the HCDR1 has the sequence of GFTFSSYAMS (SEQ ID NO:
- 33), the HCDR2 has the sequence of SITGGGGGIYYADSVKG (SEQ ID NO:
- 34), the HCDR3 has the sequence of DRISITIRPRYFGLDF (SEQ ID NO:
- 35), the LCDR1 has the sequence of RSSQNVYGNGYNYLD (SEQ ID NO:
- 42), the LCDR2 has the sequence of LGNNVAA (SEQ ID NO:
- 40), and the LCDR3 has the sequence of MQSLKAPYT (SEQ ID NO:
- 44);
- or
- the HCDR1 has the sequence of GFTFSSYAMS (SEQ ID NO:
- 33), the HCDR2 has the sequence of SITGGGGGIYYADSVKG (SEQ ID NO:
- 34), the HCDR3 has the sequence of DRISITIRPRYFGLDF (SEQ ID NO:
- 35), the LCDR1 has the sequence of RSSHNLLYSNGYNYLD (SEQ ID NO:
- 45), the LCDR2 has the sequence of LGSNRAY (SEQ ID NO:
- 46), and the LCDR3 has the sequence of MQALQSPYT (SEQ ID NO:
- 47);
- the HCDR1 has the sequence of GFTFSSYAMS (SEQ ID NO:
- 33), the HCDR2 has the sequence of SITGGGGGIYYADSVKG (SEQ ID NO:
- 34), the HCDR3 has the sequence of DRISITIRPRYFGLDF (SEQ ID NO:
- 35), the LCDR1 has the sequence of RSSQSLLYSNGYNYLD (SEQ ID NO:
- 48), the LCDR2 has the sequence of LGSNRAS (SEQ ID NO:
- 37), and the LCDR3 has the sequence of MQALETPYA (SEQ ID NO:
- 49);
- wherein the HCDR and LCDR are defined according to Kabat.
Dependencies are inferred from the claim text.